导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.98% | 3159/4765 |
| 近一周 | -1.22% | 1831/5455 |
| 近一月 | -1.25% | 1082/5411 |
| 近一季 | -0.18% | 1021/5221 |
| 近半年 | -0.71% | 1556/4910 |
| 近一年 | 0.31% | 2713/4390 |
| 近两年 | 32.71% | 2180/2953 |
| 近三年 | 20.44% | 1467/2252 |
| 成立以来 | 31.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.28% 4084/4961 |
6.64% 2810/5312 |
- - |
- - |
| 2025 | 15.27% 2559/4813 |
-0.58% 2313/3635 |
2.69% 1424/4076 |
10.72% 3252/4524 |
1.98% 1122/4813 |
| 2024 | 15.54% 917/3463 |
3.39% 581/2808 |
-0.09% 677/3014 |
16.09% 1540/3129 |
-3.65% 2374/3463 |
| 2023 | -8.21% 987/2656 |
0.86% 1680/2280 |
-4.25% 1102/2385 |
1.69% 288/2515 |
-6.54% 1820/2655 |
| 2022 | -16.10% 450/2207 |
-10.97% 464/1919 |
6.59% 657/2016 |
-12.82% 789/2113 |
1.42% 1276/2208 |
| 2021 | -4.93% 965/1822 |
-2.23% 602/1255 |
1.56% 1044/1330 |
-6.33% 915/1466 |
2.22% 655/1822 |
| 2020 | 31.05% 508/1250 |
-8.30% 596/1028 |
12.19% 695/1067 |
13.22% 337/1164 |
12.50% 461/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.65% 695/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达上证50ETF联接基金A VS. 长安沪深300非周期A(740101) |